{
  "docId": "019de072-c9ff-713b-84f0-a86291a57ca3",
  "docSlug": "36aaeca628c43c1081cab946857c1896",
  "documentTitle": "Navidea Biopharmaceuticals | Investor Presentation Deck | 18 slides",
  "authorId": "navidea-biopharmaceuticals",
  "authorName": "Navidea Biopharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 18,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines key regulatory steps including FDA meetings, Phase 3 status, and clinical trial enrollment targets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c9ff-713b-84f0-a86291a57ca3/12",
  "deckHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3",
  "deckJsonHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3.json",
  "deckAnchorHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.1,
        "y": 0.51
      },
      "kind": "callout",
      "text": "Not on critical path for FDA approval, supports adoption and biomarker designation, proof of MoA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59abd0ab-e3cf-42ff-8c29-520d44a0bf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "FDA discussion & review of Phase 3 meeting held September 1\nBegan Phase 3\nNAV3-32 Phase 2b correlation of imaging to biopsy readout ongoing\nAim for completion of Phase 3 by end of 2023 (Complete Enrollment by mid-2023)\nNDA submission targeted 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d5247d7-39e6-4fec-b1bd-fefe8c2bf7a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "RA Path to NDA Submission",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fc73e16-6ab1-4346-9521-a7ac94359ac9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 12,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "9c581025-b01b-4161-b805-cf27f7c79a9e",
      "evidence": "The section on Tc99m Tilmanocept prediction of treatment response presents it as a solution.",
      "position": 1,
      "objective": "Present Tc99m Tilmanocept as a quick win and big bet for rheumatoid arthritis treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}